You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, July 2017
|
| DOI | 10.2147/tcrm.s134398 |
| Pubmed ID | |
| Authors |
Cristina Guarnera, Placido Bramanti, Emanuela Mazzon |
| Abstract |
Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of disability showed significant reduction in the Phase II CAMMS223 and the Phase III clinical trials CARE MS I and CARE MS II. The data presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis confirmed these results. After completion of a 1-year treatment cycle, alemtuzumab showed a sustained effect. Although the efficacy of alemtuzumab has been widely proven, several severe adverse effects have been reported with its use. Infusion-associated reactions, increased risk of infections, and secondary autoimmunity have been associated with alemtuzumab. Autoimmune disease - mainly of the thyroid - has been reported. Immune thrombocytopenic purpura and autoimmune nephropathies have been observed less frequently. These adverse effects, given the short period of alemtuzumab marketing for relapsing remitting multiple sclerosis, require strict monitoring. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 50% |
| United States | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 75% |
| Members of the public | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 119 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 19 | 16% |
| Researcher | 15 | 13% |
| Student > Ph. D. Student | 13 | 11% |
| Student > Doctoral Student | 10 | 8% |
| Student > Master | 9 | 8% |
| Other | 17 | 14% |
| Unknown | 36 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 30% |
| Biochemistry, Genetics and Molecular Biology | 7 | 6% |
| Nursing and Health Professions | 7 | 6% |
| Agricultural and Biological Sciences | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 13 | 11% |
| Unknown | 46 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2021.
All research outputs
#2,788,269
of 25,382,440 outputs
Outputs from Therapeutics and Clinical Risk Management
#131
of 1,323 outputs
Outputs of similar age
#50,425
of 326,871 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 22 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,871 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.